Velasof tablet contains the active components Sofosbuvir and Velpatasvir. It is used to treat chronic hepatitis C. Hepatitis C is a liver infection caused by the hepatitis C virus (HCV). The treatment duration is often shorter than older treatment regimens. The duration can vary depending on factors such as HCV genotype, previous treatment history, and the presence of liver cirrhosis. Successful treatment with Velasof tablet can significantly reduce liver inflammation and fibrosis caused by HCV infection. By achieving viral eradication, the risk of developing liver cirrhosis, liver failure, and hepatocellular carcinoma (a type of liver cancer) can be substantially reduced.

If you have a known allergy or hypersensitivity to Velasof tablet or any of the components of the medication, you should not take it. The safety and efficacy of sofosbuvir and velpatasvir combination therapy have not been established in children under 18. Its use in the pediatric population is currently limited. It is recommended to use alternative treatment options or adjust the dosage in these cases.

To Treat Chronic Hepatitis C (HCV) Infection.

Sofosbuvir is a direct-acting antiviral drug (DAA) that inhibits the replication of the HCV virus by targeting a specific protein necessary for viral replication. Velpatasvir is also a DAA that works by blocking the action of another protein involved in the HCV replication process.

Read the instructions carefully before taking Velasof tablet. Take them as directed by your doctor. Take it with or without food. This will help to improve absorption. If you experience side effects, stop taking them and talk to your doctor.

Hepatitis B reactivation

Severe allergic reactions

Headache

Fatigue

Nausea

Insomnia

Diarrhea

Itching (pruritus)

Decreased appetite

Muscle or joint pain

Rash

Dizziness

Inform the doctor about your medicines, including prescription, over-the-counter, nutritional or vitamin supplements, and herbal products. Certain medications may interact with Velasof tablet, reducing effectiveness by causing undesirable side effects.

Stored at controlled room temperature, between 20°C to 25°C (68°F to 77°F).

Keep away from moisture, heat, and light.

It should not be frozen.

Keep away from children and pets.

Before initiating treatment, individuals should be screened for hepatitis B virus (HBV) infection due to the risk of HBV reactivation. Close monitoring of liver function and HBV DNA levels is necessary during and after treatment, particularly for those with a current or prior HBV infection. Additionally, potential drug interactions with other medications should be carefully evaluated, and healthcare providers should be informed about all current medications. Individuals taking amiodarone should be closely monitored for severe bradycardia (decreased heart rate) when co-administered with this medication. Dose adjustments are necessary for patients with severe renal impairment or end-stage renal disease. Assessing the potential impact on psychiatric health, especially in individuals with a history of psychiatric disorders, is necessary. Pregnancy and breastfeeding considerations should be discussed with a healthcare provider, and caution is advised for specific populations such as those with HIV/HCV co-infection and liver transplant recipients.